EGFR突变阳性Ⅲ期非小细胞肺癌药物治疗的研究进展OA

Non-small cell lung cancer(NSCLC)is the most common type of lung cancer,accounting for 85%of all ca-ses.Approximately 20%～30%of patients are diagnosed with stage III disease at initial presentation.According to the TNM staging system,stage III NSCLC can be further divided into stage IIIA,IIIB,and IIIC,indicating a progressively poorer prog-nosis.Stage III NSCLC is a highly heterogeneous disease.Clinically,patients are usually classified into three categories based on their eligibility for radical surgery-resectable,potentially resectable,and unresectable-leading to complex and diverse treat-ment approaches.However,with the advancement of precise targeted therapy,immunotherapy,and the promotion of the multi-disciplinary team model in lung cancer treatment,some cases of stage III NSCLC that were previously considered potentially re-sectable or unresectable may now be eligible for surgical treatment.For patients with EGFR mutation-positive unresectable stage III NSCLC,consolidation therapy with EGFR-TKIs following concurrent chemoradiotherapy has significantly prolonged both pro-gression-free survival and overall survival compared with traditional concurrent chemoradiotherapy alone.It has also demonstrated superiority over immune consolidation therapy,thereby establishing itself as a new standard of care.In addition,the"chemotherapy-free"model,which combines targeted drugs with radiotherapy,is being actively explored.Multidisciplinary collaboration and precision treatment strategies will further improve clinical outcomes for patients with stage III EGFR-mutant NSCLC.This article summarizes the current research and re-cent advances in the treatment of EGFR mutation-positive stage III NSCLC,aiming to inform further clinical research.